Automated Delineation of Putative Non-Contrast-Enhancing Tumor in Glioblastoma: Prognostic Insights
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noag042 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Maria Gómez-Mahiques und 16 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Universitario de Tecnologías de la Información y Comunicaciones (ITACA), Universitat Politècnica de València, Valencia, Spain. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Magnetic Resonance Imaging, Image Processing, Computer-Assisted. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministry of Science, Innovation and Universities, European Research Council, Helse Sør-Øst Regional Health Authority.
Abstract (Originalsprache)
Background
Precise delineation of non-contrast-enhancing tumor (nCET) in glioblastoma (GB) is critical for maximal safe resection, yet routine imaging cannot reliably separate infiltrative tumor from vasogenic edema. The aim of this study was to develop and validate an automated method to identify peritumoral subregions compatible with nCET and assess its prognostic value.
Methods
Pre-operative T2-weighted and FLAIR MRI from 940 patients with newly diagnosed GB in four multicenter cohorts were analyzed. A deep-learning model segmented enhancing tumor, edema and necrosis; a non-local, spatially varying finite mixture model was applied to identify edema subregions characterized by relatively lower FLAIR hyperintensity, hypothesized to reflect nCET-related tissue. The ratio of these subregions to total edema volume defined the T2/FLAIR Heterogeneity Index (TFHI). Associations between TFHI and overall survival (OS) were examined with Kaplan–Meier curves and multivariable Cox regression.
Results
Higher TFHI values stratified patients with shorter OS. In the NCT03439332, TFHI above the optimal threshold was associated with a twofold increased hazard of death (hazard ratio (HR) 2.07, 95 % confidence interval 1.33–3.21; p = 0.0013) and a reduction in median survival of 98 days. Significant, though smaller, prognostic effects were confirmed in GLIOCAT & BraTS (HR= 1.37; p = 0.047), OUS (HR = 1.37; p = 0.0032) and pooled analysis (HR= 1.26; p = 0.0008). TFHI remained an independent predictor after adjustment for age, extent of resection and MGMT methylation.
Conclusions
We present a reproducible, server-hosted tool for automated identification of imaging-defined, putative nCET-related peritumoral subregions and TFHI biomarker extraction that enables independent prognostic stratification. This approach provides a quantitative framework for studying peritumoral heterogeneity in GB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto Universitario de Tecnologías de la Información y Comunicaciones (ITACA), Universitat Politècnica de València, Valencia, Spain.
- Department for Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
- Vilhelm Magnus Laboratory, Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
- Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.
- Department of Radiology and IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain.
ORCID-Profile: Maria Gómez-Mahiques, Carles Lopez-Mateu, F Javier Gil-Terrón, Victor Montosa-I-Micó, Siri Fløgstad Svensson, Eduardo Erasmo Mendoza Mireles, Einar Osland Vik-Mo, Kyrre E Emblem, Carme Balañà-Quintero, Josep Puig, Cristina Alenda, Elena Martinez-Saez, Fran Martínez-Ricarte, Marta Quirós-Martí, Vicent Quilis-Quesada, Juan M García-Gómez, Elies Fuster-Garcia
Förderung
- Spanish Ministry of Science, Innovation and Universities
- European Research Council
- Helse Sør-Øst Regional Health Authority
- Research Council of Norway
- Fundació La Marató de TV3
- Instituto de Salud Carlos III
- Generalitat Valenciana
- Agencia Valenciana de la Innovación
Zitieren
APA
Gómez-Mahiques, M., Lopez-Mateu, C., Gil-Terrón, F. J., Montosa-I-Micó, V., Svensson, S. F., Mendoza Mireles, E. E., Vik-Mo, E. O., Emblem, K. E., Balañà-Quintero, C., Puig, J., Alenda, C., Martinez-Saez, E., Martínez-Ricarte, F., Quirós-Martí, M., Quilis-Quesada, V., García-Gómez, J. M., & Fuster-Garcia, E. (2026). Automated Delineation of Putative Non-Contrast-Enhancing Tumor in Glioblastoma: Prognostic Insights. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag042
Vancouver
Gómez-Mahiques M, Lopez-Mateu C, Gil-Terrón FJ, Montosa-I-Micó V, Svensson SF, Mendoza Mireles EE, et al. Automated Delineation of Putative Non-Contrast-Enhancing Tumor in Glioblastoma: Prognostic Insights. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag042
BibTeX
@article{GmezMahiques2026,
author = {Gómez-Mahiques, Maria and Lopez-Mateu, Carles and Gil-Terrón, F Javier and Montosa-I-Micó, Victor and Svensson, Siri Fløgstad and Mendoza Mireles, Eduardo Erasmo and Vik-Mo, Einar Osland and Emblem, Kyrre E and Balañà-Quintero, Carme and Puig, Josep and Alenda, Cristina and Martinez-Saez, Elena and Martínez-Ricarte, Fran and Quirós-Martí, Marta and Quilis-Quesada, Vicent and García-Gómez, Juan M and Fuster-Garcia, Elies},
title = {Automated Delineation of Putative Non-Contrast-Enhancing Tumor in Glioblastoma: Prognostic Insights},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag042}
}
EUVIMED